VERASTEM INC (VSTM) Stock Price & Overview
NASDAQ:VSTM • US92337C2035
Current stock price
The current stock price of VSTM is 5.6 USD. Today VSTM is down by -4.11%. In the past month the price decreased by -4.11%. In the past year, price decreased by -19.54%.
VSTM Key Statistics
- Market Cap
- 432.04M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.03
- Dividend Yield
- N/A
VSTM Stock Performance
VSTM Stock Chart
VSTM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VSTM. When comparing the yearly performance of all stocks, VSTM is a bad performer in the overall market: 88.82% of all stocks are doing better.
VSTM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VSTM. VSTM has a bad profitability rating. Also its financial health evaluation is rather negative.
VSTM Earnings
On February 4, 2026 VSTM reported an EPS of -0.5 and a revenue of 17.54M. The company beat EPS expectations (9.78% surprise) and beat revenue expectations (3.86% surprise).
VSTM Forecast & Estimates
15 analysts have analysed VSTM and the average price target is 16.96 USD. This implies a price increase of 202.81% is expected in the next year compared to the current price of 5.6.
For the next year, analysts expect an EPS growth of 41.93% and a revenue growth 263.25% for VSTM
VSTM Groups
Sector & Classification
VSTM Financial Highlights
Over the last trailing twelve months VSTM reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 13.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85% | ||
| ROE | -366.23% | ||
| Debt/Equity | 1.42 |
VSTM Ownership
VSTM Latest News, Press Relases and Analysis
VSTM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 388.432B | ||
| AMGN | AMGEN INC | 16.04 | 197.413B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 179.993B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 119.226B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.843B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 41.564B | ||
| INSM | INSMED INC | N/A | 30.069B | ||
| BIIB | BIOGEN INC | 11.29 | 26.644B | ||
| NTRA | NATERA INC | N/A | 26.624B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.498B | ||
| MRNA | MODERNA INC | N/A | 20.758B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.77B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.798B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VSTM
Company Profile
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Company Info
IPO: 2011-11-08
VERASTEM INC
117 Kendrick Street, Suite 500
Needham MASSACHUSETTS 02494 US
CEO: Brian M. Stuglik
Employees: 78
Phone: 17812924200
VERASTEM INC / VSTM FAQ
Can you describe the business of VERASTEM INC?
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
What is the current price of VSTM stock?
The current stock price of VSTM is 5.6 USD. The price decreased by -4.11% in the last trading session.
Does VSTM stock pay dividends?
VSTM does not pay a dividend.
What is the ChartMill technical and fundamental rating of VSTM stock?
VSTM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for VERASTEM INC?
VERASTEM INC (VSTM) operates in the Health Care sector and the Biotechnology industry.
What is VERASTEM INC worth?
VERASTEM INC (VSTM) has a market capitalization of 432.04M USD. This makes VSTM a Small Cap stock.